From AKI dosing to CKM therapeutic inertia, experts at ASN Kidney Week 2026 pointed to pharmacists as key to moving new kidney data into practice.
Commentary|Podcasts|January 6, 2026
Happy New Year from The Tell-Tale Heart!
Advertisement
Happy New Year from The Tell-Tale Heart! We'll be back in 2 weeks with a new episode. In the meantime, check out the recent episode of Drugstore Dialogue with host Barry Newman, who spoke with Craig Beavers about cardiology pharmacy.
Advertisement
Related to this article
Jai Radhakrishnan, MD, MBBS, MS, FASN, discusses why IgG4-related kidney disease is often missed and what the MITIGATE subgroup data presented at ASN Kidney Week 2026 show.
In more than 262,000 UK Biobank participants, a 5-marker cardiometabolic score was linked to graded risk at each step toward CKM multimorbidity.
Pharmacy Times featured experts on kidney function assessment, IgG4-related disease, emerging CKD therapies, and gaps in cardiorenal care.
The approval gives patients 12 years and older a once-daily oral pellet alternative to capsules for preventing hereditary angioedema (HAE) attacks.
Ravulizumab is now the first C5 complement inhibitor approved for adults with primary IgA nephropathy at risk of disease progression.
Sea buckthorn is a commonly used herbal for respiratory health—US pharmacists are knowledgeable in educating patients on herbals, especially during cold and influenza season.
Phase 3 data show pembrolizumab beats chemotherapy, offering durable first-line control with fewer severe toxicities and chemo-free potential.
Advertisement
Advertisement
Trending on Pharmacy Times
1
PCSK9 Inhibition Lowers LDL-C in Patients With Kidney Disease
2
GLP-1 RAs Tied to Lower Kidney Failure Risk in Patients With Obesity, CKD
3
Walgreens Adds Pharmacist Outreach, Coverage Help for GLP-1s
4
The Growing Role the Specialty Pharmacy Team Plays in Helping Breast Cancer Patients Navigate Treatment
5